Treatment of hepatitis C virus infection in thalassemia

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 290-299

  Butensky, Ellen ^a   Pakbaz, Zahra ^a   Foote, Drucilla ^a   Walters, Mark C ^a   Vichinsky, Elliott P ^a   Harmatz, Paul ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Bone marrow transplant; Hepatitis C virus (HCV); Interferon; Iron overload; Thalassemia

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONFERENCE PAPER; DEPRESSION; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEMOGLOBINOPATHY; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRON OVERLOAD; MEDICAL RECORD; NAUSEA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; THALASSEMIA; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 29744443924     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.038     Document Type: Conference Paper

References (43)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47: 1-39.
2. WHO. 1999. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 6: 35-47.
3. COLLINS, A.F. et al. 1994. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous beta-thalassemia. Transfusion 34: 517-520.
4. AMERICAN ACADEMY OF PEDIATRICS: COMMITTEE ON INFECTIOUS DISEASES. 1998. Hepatitis C virus infection. Pediatrics 101: 481-485.
5. WONKE, B. et al. 1990. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. J. Clin. Pathol. 43: 638-640.
6. CLEMENTE, M.G. et al. 1994. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J. Pediatr. 125: 123-128.
7. STRADER, D.B. et al. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
8. DELGADO-BORREGO, A. & M.M. JONAS. 2004. Treatment options for hepatitis C infection in children. Curr. Treat. Options Gastroenterol. 7: 373-379.
9. DI MARCO, V. et al. 1992. Alpha-interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Haematologica 77: 502-506.
10. DONOHUE, S.M. et al. 1993. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br. J. Haematol. 83: 491-497.
11. DI MARCO, V. et al. 1997. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 90: 2207-2212.
12. GIARDINI, C. et al. 1997. Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Bone Marrow Transplant. 20: 767-772.
13. SPILIOPOULOU, I. et al. 1999. Response to interferon alfa-2b therapy in multitransfused children with beta-thalassemia and chronic hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis. 18: 709-715.
14. SIEVERT, W. et al. 2002. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am. J. Gastroenterol. 97: 982-987.
15. TELFER, P.T. et al. 1997. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br. J. Haematol. 98: 850-855.
16. LI, C.K. et al. 2002. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br. J. Haematol. 117: 755-758.
17. SHERKER, A.H., M. SENOSIER & D. KERMACK. 2003. Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin. Hepatology 37: 223.
18. DESMET, V.J. et al. 1994. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 19: 1513-1520.
19. LUDWIG, J. 1993. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 105: 274-278.
20. FISCHER, R. 1998. Liver iron biosusceptometry. In Magnetism in Medicine: A Handbook, pp. 286-301. Wiley-VCH. Berlin.
21. FRIED, M.W. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36: S237-S244.
22. LJUNGMAN, P. et al. 1996. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin. Infect. Dis. 23: 167-169.
23. OLIVIERI, N.F. & G.M. BRITTENHAM. 1997. Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
24. JENSEN, P.D. et al. 1996. Serum procollagen III peptide concentration in iron overload. Eur. J. Haematol. 57: 157-164.
25. JENSEN, P.D. et al. 2003. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 101: 91-96.
26. BEINKER, N.K. et al. 1996. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J. Hepatol. 25: 633-638.
27. BONKOVSKY, H.L., B.F. BANNER & A.L. ROTHMAN. 1997. Iron and chronic viral hepatitis. Hepatology 25: 759-768.
28. ANGELUCCI, E. et al. 2002. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21.
29. LUCARELLI, G. et al. 1996. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 87: 2082-2088.
30. LUCARELLI, G. et al. 1999. Bone marrow transplantation in adult thalassemic patients. Blood 93: 1164-1167.
31. FRICKHOFEN, N. et al. 1994. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 83: 1998-2004.
32. LOCASCIULLI, A. et al. 1999. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 68: 1486-1491.
33. LOCASCIULLI, A. et al. 1995. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 16: 407-411.
34. HOOFNAGLE, J.H. et al. 2003. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 38: 66-74.
35. ZEKRI, A.R. et al. 2004. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transplant. Immunol. 13: 305-311.
36. LJUNGMAN, P. et al. 1995. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 86: 1614-1618.
37. STRASSER, S.I. et al. 1999. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 29: 1893-1899.
38. PEFFAULT DE LATOUR, R. et al. 2004. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103: 1618-1624.
39. ANGELUCCI, E. et al. 1997. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation: Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 90: 994-998.
40. WANDS, J.R. & H.E. BLUM. 1991. Primary hepatocellular carcinoma. N. Engl. J. Med. 325: 729-731.
41. PATEL, D. et al. 2005. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 3: 75-84.
42. BORGNA-PIGNATTI, C. et al. 1986. Hepatocellular carcinoma in thalassemia major. Med. Pediatr. Oncol. 14: 327-328.
43. BORGNA-PIGNATTI, C. et al. 2004. Hepatocellular carcinoma in the thalassaemia syndromes. Br. J. Haematol. 124: 114-117.